A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD

Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms HONOR
  • Sponsors Tonix Pharmaceuticals Holding Corp
  • Most Recent Events

    • 01 Nov 2017 According to a Tonix Pharmaceuticals Holding Corp media release, An unblinded interim analysis will be conducted once the study has accumulated efficacy results from approximately 275 randomized participants.
    • 29 Aug 2017 According to a Tonix Pharmaceuticals Holding Corp media release, design of this study were presented at the 2017 Military Health System Research Symposium.
    • 21 Aug 2017 According to a Tonix Pharmaceuticals Holding Corp media release, design of this study will be will presented at the 2017 Military Health System Research Symposium, August 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top